



**Texas Children's Hospital
Dermatology Service
PCP Referral Guidelines- Vitiligo**

Diagnosis: **VITILIGO**

GENERAL INFORMATION:

- It is important to note that there is no cure for vitiligo, and that despite maximal therapy, complete repigmentation is rarely achieved and that recurrence following repigmentation is likely.
- Not all children warrant active therapy. This depends on the age of the patient, location and extent, and cultural beliefs.
- If topical therapies are initiated, it may take 3-6 months of topical therapy before improvement is noted.
- Laboratory tests **are not** routinely recommended. Testing for autoimmune disease (i.e., thyroid) should be considered only if family history or clinical signs or symptoms suggest an increased risk.
- In some patients, cover-up cosmetics may be appropriate (Dermablend, Covermark).
- Emphasize importance of sun protection as affected areas are more sensitive to the sun. However, small amounts of sun exposure of affected areas (<10 minutes per day) may help repigmentation.
- JAK inhibitors (topical and systemic) are currently being studied but are not currently available in our clinic and still are not a cure for vitiligo.

TREATMENT RECOMMENDATIONS:

- For arms, legs, or trunk: Consider starting triamcinolone 0.1% ointment (or other class 2,3,4 topical steroid) twice daily for 2 weeks, with one week medication holiday, repeating this cycle for 3-6 month trial.
- For eyelids, face, groin, axilla: Consider starting Elidel 1% cream (or other calcineurin inhibitor) twice daily to affected areas.
 - Currently Medicaid is not covering calcineurin inhibitors unless patient also has a history of atopic dermatitis. If patient does not have history of atopic dermatitis 1) for eyelids, recommend deferring therapy, 2) for face, groin, axilla, can use hydrocortisone 2.5% ointment (or other class 5, 6, or 7 topical steroid) twice daily for 2 weeks, with one week medication holiday, repeating this cycle for 3-6 month trial.

REFERRAL GUIDELINES:

- Referral is not necessary if patient/family are not bothered by the appearance of vitiligo and do not wish to pursue treatment.
- If patients are responding to therapy, no referral is necessary. If inadequate improvement is seen with 3-6 month trial of topical therapy, please refer patient.

PATIENT RESOURCES: National Vitiligo Foundation www.vitiligofoundation.org



ALTERNATIVE THERAPIES

Calcineurin inhibitors	Pimecrolimus (Elidel) 1% cream Tacrolimus (Protopic) 0.03%, 0.1% ointment
------------------------	--

Potency	
Class 7 (low potency)	Hydrocortisone 1% ointment, cream Hydrocortisone 2.5% ointment, cream
Class 6 (low potency)	Alclometasone dipropionate 0.05% ointment, cream Triamcinolone acetonide 0.025% cream Triamcinolone acetonide 0.1% cream Desonide 0.05% ointment, cream Fluocinolone acetonide 0.01% ointment, cream
Class 5 (medium potency)	Betamethasone valerate 0.1% cream Clocortolone pivalate 0.1% cream Fluocinolone acetonide 0.025% cream, oil Fluticasone propionate 0.05% cream Flurandrenolide 0.05% cream Hydrocortisone butyrate 0.1% ointment, cream Hydrocortisone probutate 0.1% cream Hydrocortisone valerate 0.2% cream Prednicarbate 0.1% ointment, cream Triamcinolone 0.025% ointment
Class 4 (medium potency)	Desoximetasone 0.05% cream Fluocinolone acetonide 0.025 % ointment Flurandrenolide 0.05% ointment Hydrocortisone valerate 0.2% ointment Mometasone furoate 0.1% cream Triamcinolone acetonide 0.1% cream
Class 3 (high potency)	Amcinonide 0.1% cream Betamethasone dipropionate 0.05% cream Betamethasone valerate 0.1% ointment Diflorasone diacetate 0.05% cream Fluticasone propionate 0.005% ointment Triamcinolone acetonide 0.1% ointment Triamcinolone acetonide 0.05% cream
Class 2 (high potency)	Amcinonide 0.1% ointment Betamethasone dipropionate 0.05% ointment, cream Clobetasol propionate 0.05% solution Desoximetasone 0.025% ointment, cream Diflorasone diacetate 0.05% ointment, cream Fluocinonide 0.05% ointment, cream, solution Halcinonide 0.1% ointment, cream Mometasone furoate 0.1% ointment Triamcinolone acetonide 0.5% ointment

- Modified from Bologna JL, Jorizzo JL, Schaffer JV. Glucocorticosteroids. *Dermatology*. 3rd ed. 2012. Ch 125, p. 2079.